At least 15 biotech and pharma companies are slated to report earnings this week. Analysts expect Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to report a 4Q12 loss per share due to a 44% decline in revenues to $319 million. In 2012, demand for HCV drug Incivek telaprevir reversed course. In July, Vertex cited two factors for the decrease: doctors waiting for all-oral combination therapies and